iSpecimen Unveils Online Biospecimen Marketplace 06/13/2017
Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.Tags: biospecimen, iSpecimen, Life Sciences
add a comment
Firm client iSpecimen has launched an online biospecimen marketplace for the life sciences industry. The company hopes that the marketplace will alleviate scientists’ difficulty in finding high-quality samples of human material necessary to conduct research.
The marketplace compiles available samples and allows users to search by patient information. Users can then order the corresponding materials.
For more information about the iSpecimen Marketplace, read the full article in the BBJ, or iSpecimen’s press release.
Encore Event! Strategic Alliances: Pot of Gold or Pretty Poison? – Life Sciences Series, June 28 06/05/2017
Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Events, Life Sciences, MBBP news.Tags: biotech, John Hession, licensing, pharma, strategic alliances
add a comment
Due to overwhelming demand for our April 28 “Strategic Alliances: Pot of Gold or Pretty Poison?” event, we will be holding another round on Wednesday, June 28 at the Cambridge Innovation Center (CIC). Moderated by corporate attorney John Hession, a panel of business development experts will explore various research and collaboration structures, from options to license to comprehensive collaboration partnerships. The panel will discuss various licensing vehicles, the importance of concise fields of use descriptions, sample economics, and conventional transaction structures.
Space is limited! View our event page for more information and to register for the event.
Shann Kerner Joins MBBP as Intellectual Property Partner 05/03/2017
Posted by Morse Barnes-Brown Pendleton in Attorney News, Intellectual Property, Life Sciences, MBBP news.Tags: intellectual property attorney, intellectual property law, patent law, Shann Kerner
add a comment
We are pleased to announce the addition of Intellectual Property Member Shann Kerner.
Shann has substantial experience advising emerging, mid-sized and public companies in the biotechnology, pharmaceutical and medical device fields, counseling them on the creation, leveraging and protection of IP, with a view towards strengthening the business strategy of her clients.
A versatile and seasoned member of the Intellectual Property department, Shann concentrates her practice on IP counseling, particularly on patent portfolio procurement and management and IP due diligence in connection with venture capital, mergers and acquisitions, IPOs, and internal audits. Shann also focuses on analyses regarding patentability, freedom-to-operate, inventorship, derivation, validity and competitive subject matter landscape.
We invite you to contact Shann directly.
Applied BioMath and Northern Biologics to Collaborate on Biotherapeutic Candidate in Oncology 04/21/2017
Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.Tags: Applied BioMath, drug research, Northern Biologics
add a comment
Firm client Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, announced a collaboration with Northern Biologics, an innovative antibody discovery and development company. The companies will focus on traditional and mechanistic pharmacokinetic and pharmacodynamics (PK/PD) modeling for a biotherapeutic candidate in oncology. Applied BioMath will leverage both traditional PK/PD models and semi-mechanistic PK/PD models, while Northern Biologics will use this model to strengthen their understanding of the parameters that will determine optimal dosing paradigms.
Congratulations to our client on this new collaboration. For more information, read the full press release.
MBBP’s Life Sciences Vector Newsletter, Spring 2017 04/20/2017
Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Intellectual Property, Life Sciences, MBBP news, New Resources.Tags: Life Sciences, Life Sciences Newsletter
add a comment
Our Life Sciences team has published the Spring 2017 edition of its newsletter, Vector. Below you will find brief descriptions of the news and articles included in the publication. Read the full newsletter for more information.
DAVID CZARNECKI AND STANLEY CHALVIRE ELEVATED WITHIN THE FIRM
We are pleased to announce that David Czarnecki and Stanley Chalvire have been elevated to Member. Dave is exceptionally proficient in guiding both buyers and sellers through a wide range of corporate transactions. Stan is a Registered Patent Attorney, specializing in the licensing of intellectual property and related counseling.
AMANDA PHILLIPS NAMED 2017 UP & COMING LAWYER
Litigation associate Amanda Phillips has been named a 2017 Up & Coming Lawyer by Massachusetts Lawyers Weekly. The recognition is awarded to a select number of attorneys who have been practicing for fewer than 10 years but whose professional achievements are noteworthy and whose service to the community is also significant.
CORPORATE ATTORNEY MICHAEL JABBAWY JOINS FIRM AS PARTNER
Michael’s practice is focused primarily in the areas of emerging and growth technology companies, venture capital, M&A transactions, and corporate governance. As a member of the Corporate Department, Michael advises technology and other emerging companies through each stage of growth. Prior to joining MBBP, Michael was a member of the Technology Companies group at Goodwin Procter LLP.
RECENT LIFE SCIENCES TRANSACTIONS
MBBP represented several clients in life sciences transactions, including iSpecimen, Orionis Biosciences, First Light Biosciences, and Manus Biosynthesis. The transactions ranged from convertible debt to equity investments. Learn more on page 2.
FREEDOM TO OPERATE: PREVENTION IS THE BEST MEDICINE
Launching a new product or service can be fraught with uncertainty and involve large expenditures of limited resources. An FTO opinion can reduce uncertainty and provide some insurance against loss from an unfavorable finding of infringement of another’s patent. An FTO opinion makes a determination whether a product or service infringes issued patents. In other words, the opinion indicates whether or not there is “freedom to operate” the product or service within the patent landscape. Often, FTO opinions also identify patent applications that, if later issued as patents, may be problematic. Read the full article on page 2.
THE PATENT PROCESS: GET ON THE FAST TRACK
One of the biggest frustrations for patent applicants is the incredibly slow pace at which an application proceeds from filing to receipt of a substantive examination report to allowance. On average it takes 15.7 months for a patent application to receive even a first substantive examination report, though there is significant variability across technology areas. The Patent Office has recognized this problem and implemented several initiatives which attempt to address the problem from different angles. Two programs in particular have gained traction: the Patent Prosecution Highway (PPH) and Track One Prioritized Examination. Continue reading for more information about these programs.
OWNERSHIP OF ARISING INVENTIONS IN JOINT DEVELOPMENT AGREEMENTS
Collaboration remains a valuable means of fostering innovation and advancing scientific, clinical and commercial objectives. Towards that end, two or more parties contemplating a collaboration often consider entering into a Joint Development Agreement, where they define, among other things, their respective contributions and responsibilities towards their common objectives. These types of collaborations require a careful and thorough consideration of the disposition of intellectual property rights that may arise as a result of each party’s performance of its responsibilities under such collaborations. Read more starting on page 3.
GUEST COLUMN:
FOR SKILLED IMMIGRATION TO THE U.S., THE TIMES, THEY MAY BE CHANGING
The last year of the Obama Administration saw an increased activism by President Obama in the area of skilled immigration. Through Executive Orders and regulations, the President made a number of important changes including providing Employment Authorization for spouses on H-4 visas, increasing the period of post-graduate employment authorization for foreign students in STEM fields (Science, Technology, Engineering and Mathematics), increasing the number of academic fields included in STEM and formalizing a grace period for foreign nationals on H-1B visas that find themselves between jobs. Read the full article beginning on page 5.
Strategic Alliances: Pot of Gold or Pretty Poison? – Life Sciences Series Panel 4 Event, April 28 04/11/2017
Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Events, Licensing & Strategic Alliances, Life Sciences, MBBP news.Tags: biotech, John Hession, licensing, Life Sciences, pharma, strategic alliances
add a comment
Our Life Sciences Series Panel 4 event, Strategic Alliances: Pot of Gold or Pretty Poison?, will be held on Friday, April 28 from 7:30-10am in our Waltham office. Moderated by corporate attorney John Hession, a panel of business development experts from Big Pharma and Small Biotech explore various research and collaboration structures, from options to license to comprehensive collaboration partnerships. We will discuss various licensing vehicles, the importance of concise fields of use descriptions, sample economics, and conventional transaction structures.
View our event page for more information and to register for the event.
Early-Stage Life Science Financing: Event Recap 04/05/2017
Posted by Morse Barnes-Brown Pendleton in Corporate, Life Sciences, MBBP news.Tags: event, financing, John Hession, Life Sciences
add a comment
By: Erin Bryan
On Thursday, March 30th, MBBP kicked off an Innovations in Life Sciences event at the Cambridge Innovation Center by hosting a panel entitled “Money and Molecules: Early-Stage Life Science Financing“. The panel included Jeffrey Arnold, President & CEO of Arnold Strategies, LLC; Timothy Sullivan, Partner at Aju IB Investment; John Tagliamonte who serves on the Advisory Board of Cocoon Biotech; Caleb Winder, Managing Director of Excel Venture Management; and MBBP’s own John Hession as moderator.
The panel provided a discussion on financing strategies for young life science companies, ranging from how to get in the door with investors to what will make your company attractive for financing. It may be surprising to many, but the entire panel echoed the fact that the financing process will take longer than is generally expected. If available, it is recommended to seek grant and other non-dilutive funding in addition to any equity financing.
The panelists identified a number of factors that they consider when a company is seeking financing, including how well the company has examined the market, identified a regulatory and a reimbursement path, understood the economics of the customer, and filed for patent protection. Additional considerations include how well the company will fit with the portfolio strategy of the investor, and how complete the management team is. Many investors will also be looking to see where in the pipeline the company’s research currently is. In general, investors want to see that the company has at least reached the molecule stage and has some small animal data supporting its research, although exceptions may always be made depending on the strength of the management team, the marketing opportunity, and the science.
These were merely a few of the interesting points discussed by the panel. Save the date for our next life sciences panel “Strategic Alliances: Pot of Gold or Pretty Poison?” (the 4th in the Life Sciences Series), which will be hosted at MBBP’s Waltham office on Friday, April 28. The panel will discuss strategic alliances between big pharma and small biotech.
Early-Stage Life Science Financing Event – March 30 03/09/2017
Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Events, Life Sciences, MBBP news.Tags: early-stage companies, event, financing, life science, Life Sciences, panel, startup, startups
add a comment
Don’t miss our next event, Money and Molecules: Early-Stage Life Science Financing, on Thursday, March 30 from 3:30-5pm at the Cambridge Innovation Center. Moderated by corporate attorney John Hession, a panel of experts will discuss the current complex financing environment for early-stage life science companies. Among other topics, the panel discussion will include:
- Formulate a comprehensive and coherent financing strategy
- Construct a financing strategy that fits the company’s timetable and milestones
- Understand and handle the disadvantages of taking money from different investor types
- Understand and leverage the advantages of different classes of investors
- Optimize their chances for success
View our event page for more information and to register for the event.
Pick Up the (Patent Process) Pace! 03/07/2017
Posted by Morse Barnes-Brown Pendleton in Attorney News, Intellectual Property, Life Sciences.Tags: application, patent, prosecution, USPTO
add a comment
A common frustration for patent applicants is the incredibly slow pace at which an application proceeds from filing to receipt of a substantive examination report to allowance. On average it takes 15.7 months for a patent application to receive even a first substantive examination report! The Patent Office has recognized this problem and implemented several initiatives which attempt to address the problem from different angles. Lisa Warren, MBBP Managing Partner and Patent Attorney, discusses the Patent Prosecution Highway and the Track One program in her new article.
Interested in moving your patent application into the fast lane? Contact Lisa directly.
Dr. Kaushik Chowdhury Named as a Recipient of the Presidential Early Career Awards for Scientists and Engineers 01/31/2017
Posted by Morse Barnes-Brown Pendleton in Attorney News, Life Sciences.Tags: engineers, GENESYS Lab, National Science Foundation I-Corps, Northeastern University, PECASE, president obama, science, US government
add a comment
Morse, Barnes-Brown & Pendleton, PC congratulates Dr. Kaushik Chowdhury, Director of Northeastern University’s Next Generation Networks and Systems (GENESYS) Lab, on recently being named as a recipient of the Presidential Early Career Awards for Scientists and Engineers (PECASE) – the highest honor given by the US government to science and engineering professionals.
This summer, MBBP Partner Mike Cavaretta served as Business Mentor to Dr. Chowdhury’s team as part of the National Science Foundation’s I-Corps™ program, which offers select participants from US academic laboratories the opportunity to participate in a special, accelerated version of Stanford University’s Lean LaunchPad course. As part of this intensive program, Mike worked closely with Dr. Chowdhury and his I-Corps™ team to help move ground-breaking Radio Frequency (RF) Energy Harvesting technology developed at Dr. Chowdhury’s GENESYS Lab out of the lab and into the market.
Congratulations to Dr. Chowdhury!
MBBP client, Whitehead Institute, featured in New York Times article discussing Genomic research 01/12/2017
Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.Tags: biomedical research, client, DNA, genome, Life Sciences, new york times, scientific research, TADs, Whitehead Institute, Whitehead Institute for Biomedical Research
add a comment
The Whitehead Institute for Biomedical Research, a client of MBBP, is featured in a New York Times article about progressive research on topologically associating domains (TADs) in DNA.
As the article explains, TADs are a newly discovered design feature of the genome that partition different groups of genes into neighborhoods. If these partitions are broken, various diseases may occur.
By conducting research on TADs, scientists hope to gain a more in depth understanding of how gene expression is controlled. Dr. Richard Young of the Whitehead Institute and his team are involved in TADs research and are continuing to push the boundaries of knowledge about genetic neighborhoods.
For more information, read the full article.
MBBP’s Client Abpro Collaborating with MedImmune on Medical Advancement 12/01/2016
Posted by Morse Barnes-Brown Pendleton in Client News, Corporate, Life Sciences, Medical Devices.Tags: Abpro, antibodies, antibody, AstraZeneca, biochemistry, collaboration, DiversImmune, Ian Chan, industrial, Life Sciences, MedImmune, technology
add a comment
MBBP’s client Abpro, a pioneer in the field of industrial biochemistry, has recently entered into a Collaboration Agreement with MedImmune, the global biologics research and development arm of AstraZeneca. The collaboration will advance the development of a preclinical, novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF). Abpro will contribute its strong scientific, technical and clinical expertise to this partnership, along with its core technology platform, DiversImmuneTM, which will be utilized to further develop the bispecific antibody. Ian Chan, CEO and co-founder of Abpro, has expressed the Company’s enthusiasm towards collaborating with MedImmune, as the two businesses work together to advance these innovative therapeutics into the clinic.
For more information, read the full article.
MBBP Client Harvard Making Breakthroughs in Blood Stem Cell Research 11/21/2016
Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences, Medical Devices.Tags: boston children's hospital, david scadden, Harvard, harvard university, magenta therapeutics, massachusetts general hospital, medical field, medical technology, medicine, mgh, regenerative biology, stem cell, stem cell research, technology
add a comment
Harvard University has recently completed a license agreement with Magenta Therapeutics, a newly launched start-up in Cambridge, Massachusetts, in order to continue research and development related to new approaches to blood stem cell transplantation. The deal will help transform this science from that of a “last resort” into safer, more effective therapy for patients who suffer from blood diseases, cancers, and immune disorders. The license agreement has given Magenta the opportunity to utilize a platform of technologies developed at Harvard, Massachusetts General Hospital (MGH), and Boston Children’s Hospital.
This revolutio
nary technology has been most recently advanced in the laboratory of David Scadden, the Gerald and Darlene Jordan Professor of Medicine and professor of stem cell and regenerative biology at Harvard, and director of the Center for Regenerative Medicine at MGH. Scadden’s lab has made advances in how donor cells are selected, harvested, and prepared for transplant, improving projected outcomes for patients. For more information, read the Harvard Gazette and Boston Business Journal articles.
Client Paragonix Technologies Enters Into Distribution Agreement with Pacific West Medical Sales for Paragonix SherpaPak™ Transport Systems 11/17/2016
Posted by Morse Barnes-Brown Pendleton in Client News, Deal News, Licensing & Strategic Alliances, Life Sciences, Medical Devices.Tags: agreement, distribution, distribution agreement, pacific west medical sales, paragonix technologies
add a comment
MBBP client, Paragonix Technologies Inc. recently entered into an exclusive distribution agreement with Pacific West Medical Sales to market Paragonix Technologies’ SherpaPakTM Cardiac and Kidney Transport Systems. The SherpaPakTM Cardiac and Kidney Transport Systems are innovative medical devices that are indicated for the static hypothermic preservation of donor hearts and kidneys during transportation and eventual transplantation into a recipient.
Pacific West Medical Sales is a medical equipment sales company that provides services for hospitals, doctors’ offices, and long-term care facilities, and provides supplies for emergency medical services and home medical needs. Paragonix Technologies, is a privately held medical device company founded in 2010 and is headquartered in Braintree, Massachusetts. For more information, read the full press release.
MBBP Clients Red Crow and MiRTLE Medical Featured in Forbes Article Regarding New Equity Crowdfunding Platform 10/31/2016
Posted by Morse Barnes-Brown Pendleton in Client News, Corporate, Financial Services, Life Sciences, Venture Capital & Private Equity.Tags: biotechnology, crowd funding, crowdfunding, entrepreneur, equity, healthcare, investment, investments, jerry harrison, medtech, mirtle medical, red crow, startup, startups
add a comment
MBBP clients Red Crow and MiRTLE Medical are featured in a Forbes article regarding Red Crow’s new equity crowdfunding portal that will be launching in November. The crowdfunding platform will feature “exclusive and professionally-vetted investment opportunities” for accredited and non-accredited investors.
MiRTLE Medical will have one of the first featured investment opportunities. MiRTLE’s product is a custom designed diagnostic-grade 12-lead electrocardiogram for use during MRI. MBBP is assisting MiRTLE Medical with its involvement in the crowdfunding platform.
To learn more, read the full Forbes article.
Interview with MBBP Client Valeritas Included in Wall Street Transcript Medical Devices Report 08/09/2016
Posted by Morse Barnes-Brown Pendleton in Client News, Intellectual Property, Life Sciences, Medical Devices.Tags: Diabetes, insulin delivery, Intellectual Property, ip, John Timberlake, medical device, medical devices, medical technology, patent, type II diabetes, V-Go, Valeritas, wall street transcript
add a comment
The most recent Wall Street Transcript Medical Devices Report includes an interview with Valeritas, Inc.’s CEO, John Timberlake. Timberlake discusses in detail Valeritas’s V-Go Disposable Insulin Delivery Device. The V-Go is a wearable basal-bolus insulin delivery device that allows patients to deliver insulin at a continuous preset basal rate, with bolus delivery as needed. The V-Go has been cleared for use in the United States and in Europe. 
The fact that V-Go is a wearable product with scheduled insulin delivery enables patients to more easily go about their daily routines without having to stop to deliver insulin, and also allows them to discreetly deliver insulin during mealtimes without drawing attention to the act.
Valeritas is a commercial-stage medical technology company that develops new Type II diabetes technology products aimed at improving the lives of patients with Type II diabetes. For more information about Valeritas and its V-Go product, read the full interview with The Wall Street Transcript.
Firm Client Applied BioMath Recognized in Greater Boston’s 2016 Small Business of the Year Awards 08/02/2016
Posted by Morse Barnes-Brown Pendleton in Client News, Corporate, Life Sciences.Tags: Applied BioMath, chamber of commerce, client, drug invention, greater boston chamber of commerce, innovation, Life Sciences, small business, small business of the year awards
add a comment
MBBP is thrilled to announce that client Applied BioMath, LLC is one of ten winners of the 2016 Small Business of the Year Awards (SBOY), announced by The Greater Boston Chamber of Commerce. The SBOY recognizes smaller for-profit companies within the Greater Boston area who possess product innovation, workplace excellence, community and social responsibility, strong financial performance, and achievement in management.
Applied BioMath, LLC was founded in 2013 with the goal of transforming the quality and the economics of drug invention by applying advanced mathematical analysis at critical decision points in the drug invention process. The ten award winners will be recognized at the event “Nailed It: A Conversation with Successful Business Leaders”, which will be held on October 6th.
MBBP assisted Applied BioMath in drafting its various Service Agreements with customers, among other key legal services. Congratulations to our client in what is sure to be one of many successes!
MBBP’s Life Sciences Vector, Summer 2016 07/14/2016
Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences, MBBP news, New Resources.Tags: Life Sciences, Life Sciences Newsletter, Newsletter, Vector
add a comment
2016 LIFE SCIENCES PANEL SERIES
At the second of our Life Sciences panel Series: “Laying the Foundation for Growth: Entity & Equity”, experts discussed whether a corporation or a limited liability company is the “Right Stuff ” for building an emerging company, and how to structure and optimize the equity compensation of the team. MBBP’s John Hession moderated the panel, which included Marc Cote of Accellient and Jeff Solomon of Katz Nannis + Solomon. Stay tuned for details on Panel 3 in the fall.
Click here to learn more.
MBBP ADDS TWO ATTORNEYS
Weatherly Ralph Emans, Corporate Senior Attorney – As a member of the firm’s PIFA team in the corporate group, Weatherly focuses her practice primarily on private investment funds, including private equity funds, venture funds, hedge funds and funds of funds. Weatherly’s practice also includes venture capital transactions and providing general corporate advice to early stage companies.
Amanda R. Phillips, Litigation Associate – As a member of the firm’s litigation practice, Amanda focuses her practice on commercial civil disputes and securities litigation, and has broad experience working with clients under investigation by federal and state government agencies.
WAIT A MINUTE MR. POSTMAN…
Sooner or later many companies with a successful product or service will receive an overture from a patent holder. Some are almost friendly, proposing a potential mutually beneficial business relationship involving the patent. Others are decidedly less so, leveling claims of patent infringement and seeking immediate termination of the activity or product sales and/or significant financial compensation. This entire range of written communications is commonly referred to as “demand letters.” So – what’s the next step if your company receives a demand letter?
Read more on Page 2.
SUPREME COURT DENIES SEQUENOM’ PETITION TO CLARIFY SCOPE OF MAYO IN SEQUENOM V. ARIOSA
On June 27, 2016, the United States Supreme Court denied a Petition for Writ of Certiorari filed by Sequenom, Inc. requesting the Supreme Court to clarify the scope of its Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012) decision, as applied to Sequenom’s claimed inventions. The Mayo decision, which held that a method correlating a drug dosage regimen and levels of the drug in the blood was an unpatentable law of nature, has had the profound effect of narrowing the scope of patent-eligible subject matter in the United States and has cast doubt on the validity and enforceability of previously issued United States patents.
Read more on Page 3.
CLIENT SPOTLIGHT: iSpecimen
iSpecimen is a trusted, one-stop source of customized human biospecimen collections. Compliantly sourced from our diverse
partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations, our solid tissues, biofluids, and cells are delivered directly into the hands of biomedical researchers using our unique, turnkey technology. Scientists gain access to a ready supply of the high-quality, richly-annotated specimens they need from the patients they want. Supply partners gain an opportunity to further contribute to biomedical discovery as well as their bottom line.
Read more on Page 4.
MBBP Client BBK Worldwide Partners with Apptomics on App to Monitor Parkinson’s Patients 07/11/2016
Posted by Morse Barnes-Brown Pendleton in Client News, Computer Software & Hardware, Life Sciences, Medical Devices.Tags: app, apptomics, bbk worldwide, clinical trial, entrepreneur, neurologists, parkinson's disease, patient recruitment, patients, startup
add a comment
Firm client BBK Worldwide is partnering with Wellesley-based digital health app maker, Apptomics, as it prepares to launch a one-year clinical trial in September. Using a combination of apps (iMotor and MyPD), for monitoring patients with Parkinson’s disease, the trial will test the effectiveness of these tools in impacting the management of Parkinson’s disease and health outcomes. iMotor measures objectively patients’ motor function by combining several variables and MyPD focuses on collecting data related to symptoms, medications, side effects sleep quality, and emotional status. Data collected are transmitted in reports to patients’ neurologists.
BBK Worldwide is the foremost patient recruitment and engagement technology firm, providing a range of award-winning creative services and technology solutions to the world’s most innovative pharmaceutical and biopharmaceutical companies and their outsourced suppliers, such as CROs and eClinical providers. Apptomics works to achieve optimal management of chronic neurological conditions, including Parkinson’s, through scientifically validated mobile applications that allow collection of objective and patient reported data on disease progression. BBK Worldwide is now a minority investor in Apptomics, with BBK Principal Matthew Stumm serving on the Apptomics Board of Directors.
The two companies will work to develop a collection of apps aimed at monitoring patients with chronic neurological diseases and relaying the information to their doctors. Apptomics has already had success with the iMotor app through two studies that clearly demonstrated the scientific effectiveness of its data collection. The app also proved able to distinguish Parkinson’s patients from healthy individuals, and distinguished with high sensitivity the effects of treatment plans.
Congratulations to both companies on their new venture!
MBBP Client ConforMIS, Inc. Acknowledged for Patient Satisfaction with Knee Replacements 07/07/2016
Posted by Morse Barnes-Brown Pendleton in Client News, Employment, Life Sciences, Medical Devices.Tags: client, clinical study, ConforMIS, employment law, joint replacement implants, knee replacement, medical technology
add a comment
ConforMIS, Inc., a medical technology company that manufactures and sells joint replacement implants, received positive results from its iTotal CR study. The iTotal CR is a fully customized implant for use in total knee replacement, and the study found that 92% of patients were satisfied with the product in the year after receiving a knee replacement. 
In developing, manufacturing, and selling joint replacement implants, ConforMIS uses its iFit Image-to-Implant technology, which allows for a customized implant specifically designed to fit an individual’s anatomy. The iTotal CR study included 300 patients in the United States, and is still ongoing. The interim study results were presented at the 2016 SICOT International Orthopaedic “Specialized Knee Surgery” Conference in Germany, which ran from June 30th to July 2nd.
The positive feedback is consistent with a previous study that showed that patients noted significantly higher satisfaction with the ConforMIS iTotal CR in their knee replacements, than with off-the-shelf implants. The positive results speak to the benefits of anatomically customized implants, and illustrate how ConforMIS’s products are making a positive and lasting impact in the joint replacement implant market.
To read more about the study and ConforMIS’s technology, read the full article.
